Trade OptiNose - OPTN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
OptiNose Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.22 |
Open* | 1.21 |
1-Year Change* | -30.06% |
Day's Range* | 1.21 - 1.23 |
52 wk Range | 0.90-2.07 |
Average Volume (10 days) | 217.39K |
Average Volume (3 months) | 5.75M |
Market Cap | 137.02M |
P/E Ratio | -100.00K |
Shares Outstanding | 112.31M |
Revenue | 71.98M |
EPS | -0.39 |
Dividend (Yield %) | N/A |
Beta | -0.16 |
Next Earnings Date | Mar 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 1.23 | 0.02 | 1.65% | 1.21 | 1.23 | 1.20 |
Nov 30, 2023 | 1.22 | -0.01 | -0.81% | 1.23 | 1.24 | 1.20 |
Nov 29, 2023 | 1.22 | 0.03 | 2.52% | 1.19 | 1.22 | 1.18 |
Nov 28, 2023 | 1.21 | -0.01 | -0.82% | 1.22 | 1.22 | 1.18 |
Nov 27, 2023 | 1.18 | -0.02 | -1.67% | 1.20 | 1.22 | 1.15 |
Nov 24, 2023 | 1.21 | 0.01 | 0.83% | 1.20 | 1.22 | 1.20 |
Nov 22, 2023 | 1.20 | 0.03 | 2.56% | 1.17 | 1.21 | 1.17 |
Nov 21, 2023 | 1.19 | 0.02 | 1.71% | 1.17 | 1.21 | 1.14 |
Nov 20, 2023 | 1.15 | -0.04 | -3.36% | 1.19 | 1.22 | 1.13 |
Nov 17, 2023 | 1.22 | -0.01 | -0.81% | 1.23 | 1.24 | 1.20 |
Nov 16, 2023 | 1.22 | 0.02 | 1.67% | 1.20 | 1.23 | 1.19 |
Nov 15, 2023 | 1.22 | 0.02 | 1.67% | 1.20 | 1.23 | 1.19 |
Nov 14, 2023 | 1.22 | 0.00 | 0.00% | 1.22 | 1.23 | 1.17 |
Nov 13, 2023 | 1.20 | 0.02 | 1.69% | 1.18 | 1.25 | 1.18 |
Nov 10, 2023 | 1.19 | -0.01 | -0.83% | 1.20 | 1.20 | 1.15 |
Nov 9, 2023 | 1.20 | -0.09 | -6.98% | 1.29 | 1.29 | 1.20 |
Nov 8, 2023 | 1.21 | 0.02 | 1.68% | 1.19 | 1.23 | 1.13 |
Nov 7, 2023 | 1.19 | 0.03 | 2.59% | 1.16 | 1.19 | 1.14 |
Nov 6, 2023 | 1.16 | -0.07 | -5.69% | 1.23 | 1.23 | 1.14 |
Nov 3, 2023 | 1.22 | -0.01 | -0.81% | 1.23 | 1.24 | 1.19 |
OptiNose Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, March 5, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 OptiNose Inc Earnings Release Q4 2023 OptiNose Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 76.276 | 74.652 | 49.117 | 34.631 | 7.065 |
Revenue | 76.276 | 74.652 | 49.117 | 34.631 | 7.065 |
Total Operating Expense | 132.172 | 141.102 | 136.336 | 137.387 | 107.305 |
Selling/General/Admin. Expenses, Total | 107.649 | 106.633 | 105.438 | 104.155 | 95.618 |
Research & Development | 15.26 | 25.318 | 23.378 | 20.783 | 10.099 |
Operating Income | -55.896 | -66.45 | -87.219 | -102.756 | -100.24 |
Interest Income (Expense), Net Non-Operating | -17.541 | -15.921 | -12.566 | -7.297 | -6.824 |
Other, Net | -1.396 | 0.075 | 0 | 0.406 | |
Net Income Before Taxes | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Net Income After Taxes | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Net Income Before Extra. Items | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Net Income | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Total Adjustments to Net Income | 0 | ||||
Income Available to Common Excl. Extra. Items | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Income Available to Common Incl. Extra. Items | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Dilution Adjustment | |||||
Diluted Net Income | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Diluted Weighted Average Shares | 85.9001 | 56.8519 | 48.2752 | 41.8775 | 39.766 |
Diluted EPS Excluding Extraordinary Items | -0.87116 | -1.44755 | -2.067 | -2.62797 | -2.68214 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -0.87116 | -1.44755 | -2.067 | -2.45712 | -2.68214 |
Cost of Revenue, Total | 9.263 | 9.151 | 7.52 | 5.294 | 1.588 |
Gross Profit | 67.013 | 65.501 | 41.597 | 29.337 | 5.477 |
Unusual Expense (Income) | 0 | 7.155 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 19.454 | 11.845 | 20.856 | 20.078 | 20.582 |
Revenue | 19.454 | 11.845 | 20.856 | 20.078 | 20.582 |
Cost of Revenue, Total | 2.571 | 1.706 | 2.981 | 2.125 | 2.143 |
Gross Profit | 16.883 | 10.139 | 17.875 | 17.953 | 18.439 |
Total Operating Expense | 23.626 | 26.215 | 29.212 | 30.878 | 35.927 |
Selling/General/Admin. Expenses, Total | 20.104 | 22.724 | 23.31 | 25.486 | 29.514 |
Research & Development | 0.951 | 1.785 | 2.921 | 3.267 | 4.27 |
Operating Income | -4.172 | -14.37 | -8.356 | -10.8 | -15.345 |
Interest Income (Expense), Net Non-Operating | 6.798 | -4.48 | -5.397 | -4.154 | -4.052 |
Net Income Before Taxes | 2.626 | -18.85 | -15.149 | -14.954 | -19.397 |
Net Income After Taxes | 2.626 | -18.85 | -15.149 | -14.954 | -19.397 |
Net Income Before Extra. Items | 2.626 | -18.85 | -15.149 | -14.954 | -19.397 |
Net Income | 2.626 | -18.85 | -15.149 | -14.954 | -19.397 |
Income Available to Common Excl. Extra. Items | 2.573 | -18.797 | -15.149 | -14.954 | -19.397 |
Income Available to Common Incl. Extra. Items | 2.573 | -18.797 | -15.149 | -14.954 | -19.397 |
Diluted Net Income | 2.573 | -18.797 | -15.149 | -14.954 | -19.397 |
Diluted Weighted Average Shares | 112.042 | 111.96 | 95.06 | 83.3207 | 82.7401 |
Diluted EPS Excluding Extraordinary Items | 0.02296 | -0.16789 | -0.15936 | -0.17948 | -0.23443 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.02296 | -0.16789 | -0.15936 | -0.17948 | -0.23443 |
Gain (Loss) on Sale of Assets | 0 | 0 | |||
Other, Net | -1.396 | ||||
Total Adjustments to Net Income | -0.053 | 0.053 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 140.484 | 160.379 | 180.652 | 168.06 | 212.857 |
Cash and Short Term Investments | 94.244 | 110.502 | 144.156 | 147.144 | 200.99 |
Cash & Equivalents | 94.244 | 110.502 | 144.156 | 147.144 | 200.99 |
Total Receivables, Net | 33.932 | 35.449 | 23.394 | 13.818 | 2.552 |
Accounts Receivable - Trade, Net | 33.932 | 35.449 | 23.394 | 13.818 | 2.552 |
Prepaid Expenses | 2.865 | 2.568 | 4.037 | 3.593 | 2.162 |
Total Assets | 144.222 | 166.071 | 188.813 | 172.65 | 216.989 |
Property/Plant/Equipment, Total - Net | 3.24 | 5.398 | 8.006 | 4.438 | 3.884 |
Property/Plant/Equipment, Total - Gross | 7.805 | 9.681 | 11.792 | 6.685 | 5.035 |
Accumulated Depreciation, Total | -4.565 | -4.283 | -3.786 | -2.247 | -1.151 |
Other Long Term Assets, Total | 0.498 | 0.294 | 0.155 | 0.152 | 0.248 |
Total Current Liabilities | 178.73 | 59.235 | 52.172 | 36.139 | 25.697 |
Accounts Payable | 5.291 | 8.013 | 5.489 | 3.625 | 7.116 |
Accrued Expenses | 44.864 | 51.222 | 46.683 | 32.514 | 18.421 |
Notes Payable/Short Term Debt | 128.575 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.16 | |||
Total Liabilities | 200.846 | 187.843 | 182.025 | 111.067 | 98.378 |
Total Long Term Debt | 0 | 126.418 | 125.202 | 74.531 | 72.5 |
Long Term Debt | 0 | 126.418 | 125.202 | 74.531 | 72.5 |
Other Liabilities, Total | 22.116 | 2.19 | 4.651 | 0.397 | 0.181 |
Total Equity | -56.624 | -21.772 | 6.788 | 61.583 | 118.611 |
Redeemable Preferred Stock | |||||
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.111 | 0.082 | 0.053 | 0.046 | 0.041 |
Additional Paid-In Capital | 628.242 | 588.288 | 534.585 | 489.565 | 436.554 |
Retained Earnings (Accumulated Deficit) | -684.893 | -610.061 | -527.765 | -427.98 | -317.927 |
Other Equity, Total | -0.084 | -0.081 | -0.085 | -0.048 | -0.057 |
Total Liabilities & Shareholders’ Equity | 144.222 | 166.071 | 188.813 | 172.65 | 216.989 |
Total Common Shares Outstanding | 111.493 | 82.2389 | 52.9459 | 41.2275 | 37.8026 |
Total Inventory | 9.443 | 11.847 | 9.042 | 3.484 | 7.132 |
Other Current Assets, Total | 0.013 | 0.023 | 0.021 | 0.021 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 98.62 | 103.61 | 112.171 | 140.484 | 100.931 |
Cash and Short Term Investments | 66.845 | 71.311 | 83.928 | 94.244 | 61.08 |
Cash & Equivalents | 66.845 | 71.311 | 83.928 | 94.244 | 61.08 |
Total Receivables, Net | 21.373 | 22.128 | 16.979 | 33.932 | 26.616 |
Accounts Receivable - Trade, Net | 21.373 | 22.128 | 16.979 | 33.932 | 26.616 |
Total Inventory | 8.043 | 7.732 | 8.303 | 9.443 | 10.415 |
Prepaid Expenses | 2.359 | 2.439 | 2.961 | 2.865 | 2.779 |
Other Current Assets, Total | 0.041 | ||||
Total Assets | 101.407 | 106.068 | 114.925 | 144.222 | 105.27 |
Property/Plant/Equipment, Total - Net | 0.882 | 0.723 | 0.722 | 3.24 | 0.901 |
Property/Plant/Equipment, Total - Gross | 5.659 | 5.422 | 5.347 | 7.805 | 5.354 |
Accumulated Depreciation, Total | -4.777 | -4.699 | -4.625 | -4.565 | -4.453 |
Other Long Term Assets, Total | 1.905 | 1.735 | 2.032 | 0.498 | 3.438 |
Total Current Liabilities | 163.981 | 164.299 | 166.303 | 178.73 | 177.795 |
Accounts Payable | 5.006 | 6.482 | 6.244 | 5.291 | 8.403 |
Accrued Expenses | 29.162 | 28.423 | 31.08 | 44.864 | 41.285 |
Notes Payable/Short Term Debt | 129.813 | 129.394 | 128.979 | 128.575 | 128.107 |
Total Liabilities | 179.022 | 175.728 | 188.71 | 200.846 | 178.686 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | 0 | |||
Other Liabilities, Total | 15.041 | 11.429 | 22.407 | 22.116 | 0.891 |
Total Equity | -77.615 | -69.66 | -73.785 | -56.624 | -73.416 |
Common Stock | 0.112 | 0.112 | 0.112 | 0.111 | 0.084 |
Additional Paid-In Capital | 632.765 | 631.426 | 629.927 | 628.242 | 596.329 |
Retained Earnings (Accumulated Deficit) | -710.408 | -701.114 | -703.74 | -684.893 | -669.745 |
Other Equity, Total | -0.084 | -0.084 | -0.084 | -0.084 | -0.084 |
Total Liabilities & Shareholders’ Equity | 101.407 | 106.068 | 114.925 | 144.222 | 105.27 |
Total Common Shares Outstanding | 112.312 | 112.092 | 111.956 | 111.493 | 83.5205 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -74.833 | -82.296 | -99.785 | -110.053 | -106.658 |
Cash From Operating Activities | -67.651 | -76.935 | -86.206 | -90.815 | -91.817 |
Cash From Operating Activities | 0.532 | 0.646 | 1.456 | 1.108 | 0.539 |
Non-Cash Items | 12.406 | 11.498 | 12.219 | 17.673 | 8.947 |
Changes in Working Capital | -5.756 | -6.783 | -0.096 | 0.457 | 5.355 |
Cash From Investing Activities | -0.063 | -0.062 | -0.546 | -0.557 | -1.69 |
Capital Expenditures | -0.063 | -0.167 | -0.546 | -0.557 | -1.69 |
Cash From Financing Activities | 51.436 | 43.32 | 83.81 | 37.529 | 59.579 |
Financing Cash Flow Items | -0.298 | -0.227 | -0.883 | -5.776 | -6.617 |
Issuance (Retirement) of Stock, Net | 51.18 | 43.179 | 88.275 | 45.888 | 66.196 |
Issuance (Retirement) of Debt, Net | 0.554 | 0.368 | -3.582 | -2.583 | 0 |
Foreign Exchange Effects | 0.007 | 0.013 | -0.044 | -0.003 | 0.064 |
Net Change in Cash | -16.271 | -33.664 | -2.986 | -53.846 | -33.864 |
Cash Interest Paid | 15.091 | 14.17 | 11.561 | 8.785 | 8.253 |
Other Investing Cash Flow Items, Total | 0 | 0.105 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.847 | -74.833 | -59.684 | -44.73 | -25.333 |
Cash From Operating Activities | -10.478 | -67.651 | -49.971 | -32.473 | -19.335 |
Cash From Operating Activities | 0.072 | 0.532 | 0.4 | 0.256 | 0.119 |
Non-Cash Items | 2.438 | 12.406 | 9.08 | 6.509 | 2.533 |
Changes in Working Capital | 5.859 | -5.756 | 0.233 | 5.492 | 3.346 |
Cash From Investing Activities | 0 | -0.063 | -0.06 | -0.05 | -0.048 |
Capital Expenditures | 0 | -0.063 | -0.06 | -0.05 | -0.048 |
Cash From Financing Activities | 0.162 | 51.436 | 0.649 | 0.276 | 0.249 |
Financing Cash Flow Items | -0.298 | 0 | 0.027 | 0 | |
Issuance (Retirement) of Debt, Net | 0.554 | ||||
Foreign Exchange Effects | 0 | 0.007 | -0.012 | 0.003 | -0.003 |
Net Change in Cash | -10.316 | -16.271 | -49.394 | -32.244 | -19.137 |
Other Investing Cash Flow Items, Total | 0 | 0 | 0 | ||
Issuance (Retirement) of Stock, Net | 0.162 | 51.18 | 0.649 | 0.249 | 0.249 |
Cash Interest Paid | 4.255 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 13.1892 | 14801306 | -54172 | 2023-06-30 | LOW |
MVM Partners LLP | Venture Capital | 13.0145 | 14605263 | 300 | 2022-12-31 | LOW |
Great Point Partners, LLC | Hedge Fund | 7.8771 | 8839939 | 945203 | 2023-06-30 | HIGH |
Kruttschnitt (Theodore H III) | Individual Investor | 6.0734 | 6815789 | 2649613 | 2022-12-31 | |
Rosalind Advisors, Inc. | Hedge Fund | 5.7341 | 6435000 | 6435000 | 2023-07-11 | LOW |
Acorn Bioventures L.P. | Venture Capital | 5.6775 | 6371463 | 6371463 | 2022-11-23 | HIGH |
Bleichroeder LP | Investment Advisor | 3.6045 | 4045132 | 0 | 2023-06-30 | LOW |
Kingdon Capital Management, L.L.C. | Hedge Fund | 3.2518 | 3649237 | 0 | 2023-06-30 | HIGH |
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 3.2051 | 3596861 | 100000 | 2023-06-30 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.2025 | 3593922 | 448541 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.1602 | 3546526 | 2958022 | 2023-06-30 | LOW |
Medical Strategy GmbH | Investment Advisor | 2.8894 | 3242548 | -911950 | 2023-05-31 | MED |
MFS Investment Management | Investment Advisor/Hedge Fund | 2.5362 | 2846183 | -28747 | 2023-06-30 | LOW |
Nantahala Capital Management, LLC | Hedge Fund | 2.3896 | 2681667 | 1231667 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2658 | 1420495 | 698450 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.0967 | 1230713 | 1023560 | 2023-06-30 | LOW |
GMT Capital Corp. | Hedge Fund | 0.9897 | 1110702 | 1087414 | 2023-06-30 | LOW |
Rice Hall James & Associates, LLC | Investment Advisor/Hedge Fund | 0.8614 | 966723 | 194763 | 2023-06-30 | LOW |
Miller (Peter K) | Individual Investor | 0.7017 | 787415 | 252830 | 2023-04-18 | LOW |
Easterly Investment Partners LLC | Investment Advisor | 0.66 | 740641 | 5640 | 2023-03-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
OptiNose Company profile
About OptiNose Inc
OptiNose, Inc. is a specialty pharmaceutical company that is focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company’s products candidates include XHANCE (fluticasone propionate) and ONZETRA Xsail. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 mcg, is therapeutic utilizing its proprietary exhalation delivery system (EDS) device that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, OptiNose Inc revenues increased 52% to $74.7M. Net loss decreased 18% to $82.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 13% to $1.1M (expense), Stock-based Compensation in SGA decrease of 1% to $8.9M (expense).
Industry: | Pharmaceuticals (NEC) |
1020 Stony Hill Rd Ste 300
YARDLEY
PENNSYLVANIA 19067-5539
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com